A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

NCT01882803 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-Hodgkin Lymphoma

Interventions

DRUG: Duvelisib

Sponsor

SecuraBio